I was comparing the percent of FLT3 genes in AML from TCGA data with the mutations found in our exome data. Our exome data only reveals less than 50% of FLT3 mutations compared to TCGA samples. Does anyone know what capture method TCGA consortium used for AML samples? Is there any reason why we can't see half of FLTs in our cohort compared to TCGA? Also, what could be the reasons that all mutations in FLT3 can't be determined by exome methods?